CRISPR Therapeutics AG (CRSP)
53.39
+2.95
(+5.85%)
USD |
NASDAQ |
Oct 09, 16:00
53.37
-0.02
(-0.04%)
After-Hours: 20:00
CRISPR Therapeutics Cash from Operations (Quarterly) : -83.50M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -83.50M |
| March 31, 2026 | -108.90M |
| December 31, 2025 | -92.55M |
| September 30, 2025 | -84.63M |
| June 30, 2025 | -113.88M |
| March 31, 2025 | -53.95M |
| December 31, 2024 | -50.03M |
| September 30, 2024 | -106.91M |
| June 30, 2024 | -95.58M |
| March 31, 2024 | 109.75M |
| December 31, 2023 | -96.07M |
| September 30, 2023 | -39.86M |
| June 30, 2023 | -133.24M |
| March 31, 2023 | 8.799M |
| December 31, 2022 | -113.33M |
| September 30, 2022 | -105.22M |
| June 30, 2022 | -141.96M |
| March 31, 2022 | -135.24M |
| December 31, 2021 | -86.04M |
| September 30, 2021 | -81.33M |
| June 30, 2021 | 807.00M |
| March 31, 2021 | -100.66M |
| December 31, 2020 | -81.21M |
| Date | Value |
|---|---|
| September 30, 2020 | -75.70M |
| June 30, 2020 | -29.28M |
| March 31, 2020 | -52.18M |
| December 31, 2019 | 3.376M |
| September 30, 2019 | 133.42M |
| June 30, 2019 | -36.38M |
| March 31, 2019 | -43.74M |
| December 31, 2018 | -28.37M |
| September 30, 2018 | -19.96M |
| June 30, 2018 | -25.22M |
| March 31, 2018 | -22.69M |
| December 31, 2017 | -14.84M |
| September 30, 2017 | -15.87M |
| June 30, 2017 | -15.97M |
| March 31, 2017 | -23.41M |
| December 31, 2016 | -21.87M |
| September 30, 2016 | -9.823M |
| June 30, 2016 | -13.60M |
| March 31, 2016 | -10.01M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | -2.68M |
| March 31, 2015 | -1.583M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -55.66M |
| Cash from Financing (Quarterly) | 7.18M |
| Free Cash Flow | -371.32M |
| Free Cash Flow Per Share (Quarterly) | -0.8719 |
| Free Cash Flow to Equity (Quarterly) | -80.25M |
| Free Cash Flow to Firm (Quarterly) | -84.15M |
| Free Cash Flow Yield | -7.34% |